Niva Bupa Health Insurance Company
H1 FY27 PAT doubled to ₹273 Cr; GWP up 26% ex-1/n. Loss ratio gains credited to mix; management declined to quantify drivers. Solvency drifting down to 2.03x is the watch item.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Niva Bupa Health Insurance Company earnings call we streamed: the live audio and our summary of what management said.
H1 FY27 PAT doubled to ₹273 Cr; GWP up 26% ex-1/n. Loss ratio gains credited to mix; management declined to quantify drivers. Solvency drifting down to 2.03x is the watch item.
H1 FY27 PAT doubled to ₹273 Cr; GWP up 26% ex-1/n. Loss ratio gains credited to mix; management declined to quantify drivers. Solvency drifting down to 2.03x is the watch item.
No numeric growth guidance; ROE target mid-to-high teens; October retail growth 'in the 30s'; yield 7.4-7.5% sustainable.
Niva Bupa reported strong Q1 FY27 results with 31.7% reported growth and PAT improving to INR 137.8 crores. Management focused on retail health expansion and transition to Ind AS accounting.
Niva Bupa reported strong Q4 FY26 results with PAT growing 90% YoY to ₹366cr for the full year. Strategy focuses on multichannel distribution and digital growth.
Niva Bupa Health Insurance reported FY26 Net Profit of ₹13,078 lakhs on Gross Premiums of ₹8,58,592 lakhs. Focus remains on retail health and solvency management.
Niva Bupa achieved 27.4% GWP growth to ₹9,433 Cr and 80.4% PAT growth to ₹366.1 Cr (IFRS) in FY26, driven by retail health expansion and improved efficiencies.
Niva Bupa reported stellar FY26 performance with GWP of ₹9,433 crore and PAT of ₹366 crore (IFRS). Strategy focuses on multi-channel distribution, digital automation, and LTV-based underwriting to drive profitability.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.